Bolaman Zahit, Kadikoylu Gurhan, Ozgel Nihat, Yenisey Cigdem
Division of Hematology, Department of Internal Medicine, Adnan Menderes University Medical School, 09100 Aydin, Turkey.
J Natl Med Assoc. 2006 Aug;98(8):1273-7.
The mechanism of the antithrombotic action of statins is unclear. We evaluated the effects of atorvastatin on the coagulation parameters and homocysteine levels of patients with primary hypercholesterolemia.
Forty-four patients with primary hypercholesterolemia were treated with atorvastatin 10 mg/d for 24 weeks at Adnan Menderes University Medical Faculty, Division of Hematology, Aydin, Turkey. We evaluated the effects of atorvastatin on homocysteine; lipid parameters such as total cholesterol, low-density-lipoprotein (LDL) cholesterol, very-low-density-lipoprotein (VLDL) cholesterol, triglycerides, high-density-lipoprotein (HDL) cholesterol, lipoprotein (a), apolipoprotein Al and apolipoprotein B; and coagulation parameters such as fibrinogen, antithrombin-III, protein C, protein S, von Willebrand factor, D-dimer, partial thromboplastin time and prothrombin time; and hematological parameters such as hemoglobin, white blood cell and platelet counts, vitamin B12 and folic acid.
Atorvastatin significantly decreased the levels of total cholesterol, LDL cholesterol (p < 0.001), VLDL cholesterol, triglycerides and apo B (p < 0.001). The level of HDL cholesterol significantly increased with atorvastatin treatment (p < 0.001). Atorvastatin significantly increased the levels of fibrinogen (p < 0.001), but it had no effect on other coagulation factors and homocysteine (p > 0.05). After treatment, while vitamin B12 levels significantly increased (p < 0.05), other hematological parameters were not changed with atorvastatin (p > 0.05).
Although there were beneficial effects of atorvastatin on lipid parameters, atorvastatin did not significantly change the level of homocysteine and hematological, and coagulation parameters, with the exception of fibrinogen and vitamin B12 levels.
他汀类药物抗血栓形成作用的机制尚不清楚。我们评估了阿托伐他汀对原发性高胆固醇血症患者凝血参数和同型半胱氨酸水平的影响。
在土耳其艾登市阿德南·门德雷斯大学医学院血液科,44例原发性高胆固醇血症患者接受10mg/d阿托伐他汀治疗24周。我们评估了阿托伐他汀对同型半胱氨酸;血脂参数,如总胆固醇、低密度脂蛋白(LDL)胆固醇、极低密度脂蛋白(VLDL)胆固醇、甘油三酯、高密度脂蛋白(HDL)胆固醇、脂蛋白(a)、载脂蛋白A1和载脂蛋白B;凝血参数,如纤维蛋白原、抗凝血酶III、蛋白C、蛋白S、血管性血友病因子、D-二聚体、部分凝血活酶时间和凝血酶原时间;以及血液学参数,如血红蛋白、白细胞和血小板计数、维生素B12和叶酸的影响。
阿托伐他汀显著降低了总胆固醇、LDL胆固醇(p<0.001)、VLDL胆固醇、甘油三酯和载脂蛋白B的水平(p<0.001)。阿托伐他汀治疗后HDL胆固醇水平显著升高(p<0.001)。阿托伐他汀显著提高了纤维蛋白原水平(p<0.001),但对其他凝血因子和同型半胱氨酸没有影响(p>0.05)。治疗后,维生素B12水平显著升高(p<0.05),而其他血液学参数阿托伐他汀未使其改变(p>0.05)。
尽管阿托伐他汀对血脂参数有有益作用,但除纤维蛋白原和维生素B12水平外,阿托伐他汀并未显著改变同型半胱氨酸水平以及血液学和凝血参数。